Product
Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes
1 clinical trial
9 indications
Indication
Acute Biphenotypic LeukemiaIndication
Acute Myeloid LeukemiaIndication
Adult Acute Myeloid LeukemiaIndication
Acute Lymphoblastic LeukemiaIndication
IL-3RαIndication
MRDIndication
Adult Acute Myeloid Leukemia (AML)Clinical trial
Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With CD123+ Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell NeoplasmStatus: Active (not recruiting), Estimated PCD: 2024-12-15